Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ACTRN12626000328370) titled 'A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered LW-1017 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of LW-1017 in Healthy Volunteers' on March 16.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: Lysoway Therapeutics Pty Ltd
Condition:
Neurodegenerative diseases
Neurodegenerative diseases
Neurological - Alzheimer's disease
Neurological - Parkinson's disease
Intervention:
This is a double-blind, randomised, p...